Targeting transfer RNA-derived fragments during KSHV infection

点击翻译按钮获取中文摘要

Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic virus required for the development of Kaposi's sarcoma (KS). There are no specific KSHV antivirals or vaccines and current treatments for KSHV-associated diseases are not targeted, relying on rebuilding the immune system and using cytotoxic agents. As KS is an AIDS-defining disease, controlling HIV/AIDS using immune reconstitution has been investigated as a KS treatment. However, even with effective Antiretroviral Therapy (ART) and well-controlled HIV infection, many patients still develop progressive KS. HIV-KS patients can also exhibit a worsening of symptoms upon ART, developing KS-associated immune reconstitution inflammatory syndrome, now a major contributor to KSHV-associated deaths. Consequently, anti-KSHV therapies are urgently needed. Like all herpesviruses KSHV has two distinct life cycles, a persistence life-long infection (latency) and infectious productive cycle (lytic replication). Lytic replication plays an important part in KSHV pathogenesis. Therefore, it is essential to study the molecular mechanisms which regulate lytic replication. Moreover, inhibiting KSHV lytic replication may provide an opportunity to develop novel antiviral strategies to inhibit KS formation. We have exciting data demonstrating that KSHV manipulates a recently classified group of non-coding RNAs, termed transfer RNA-derived small RNA fragments (tRFs), to enhance lytic replication. tRFs are derived from precursor or mature tRNAs and are implicated in multiple biological pathways, functioning as regulators of gene expression. Not surprisingly abnormal tRF levels are identified in a wide range of human diseases, including cancer, metabolic and neurological diseases and infections. However, it remains to be determined how tRF biogenesis is regulated and how tRF dysregulation contributes to disease. Therefore, KSHV manipulation of tRF levels presents an novel opportunity to examine how tRF dysregulation impacts gene expression and how this leads to disease. Moreover, reversing the effect of KSHV-mediated tRF dysregulation reduces virus replication, suggesting it has potential as a novel antiviral strategy.Five structural categories of tRFs have been reported and our preliminary results demonstrate that KSHV specifically dysregulates two distinct tRF subtypes. Firstly, we observe a specific downregulation of 3'-tRFs, and due to their small size and association with Argonaute proteins we believe they may function in a similar manner to miRNAs to regulate gene expression during infection. We will identify mRNA targets of these dysregulated 3'-tRFs and then assess their role in virus replication. In contrast, we observe an upregulation of a second tRF subset, i-tRFs. i-tRFs fail to associate with Argonaute proteins and instead contain conserved RNA binding protein (RBP) motifs, suggesting they function as RBP sponges. We will identify cellular RBPs which bind these upregulated i-tRFs and assess what effect RBP sequestration has on virus replication and transcriptome-wide gene expression. Moreover, we will investigate novel mechanisms of how KSHV manipulates tRF levels during infection. Finally, we show that reversing the effect of tRF dysregulation has a detrimental effect on virus replication. Therefore, we will optimise the best approach to reverse tRF dysregulation in KSHV-infected cell lines and a 3D tumour model to validate this approach as a novel antiviral strategy. In summary, this project will identify novel ways KSHV can manipulate the host cell to enhance its own replication and provide a better understanding of how tRFs regulate gene expression. This will impact on our understanding of the emerging role of tRFs in cell and developmental processes, the development of human disease and provide new strategies for therapeutic intervention of an important human pathogen.